• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Booth, Catherine
    Booth, Dawn
    Williamson, S
    Demchyshyn, L L
    Potten, Christopher S
    Affiliation
    Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
    Issue Date
    2004-12
    
    Metadata
    Show full item record
    Abstract
    Glucagon-like peptide-2 and its dipeptidyl peptidase (DP-IV) resistant analogue teduglutide are trophic for the gastrointestinal epithelium. Exposure increases villus height and crypt size and results in increased overall intestinal weight. As these effects may be mediated through stimulation of the stem cell compartment, they may promote intestinal healing and act as potential anti-mucositis agents in patients undergoing cancer chemotherapy. A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence. Teduglutide demonstrated intestinotrophic effects in both CD1 and BDF1 mouse strains. In BDF1 mice, subcutaneous injection of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days increased intestinal weight by 28% and resulted in comparable increases in crypt size, villus height and area. Teduglutide given daily for 6 or 14 days prior to whole body, gamma-irradiation significantly increased crypt stem cell survival when compared with vehicle-treated controls. The mean levels of protection over a range of doses provided protection factors from 1.3 to 1.5. A protective effect was only observed when teduglutide was given before irradiation. These results suggest that teduglutide has the ability to modulate clonogenic stem cell survival in the small intestine and this may have a useful clinical application in the prevention of cancer therapy-induced mucositis.
    Citation
    Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. 2004, 37 (6):385-400 Cell Prolif.
    Journal
    Cell Proliferation
    URI
    http://hdl.handle.net/10541/78153
    DOI
    10.1111/j.1365-2184.2004.00320.x
    PubMed ID
    15548172
    Type
    Article
    Language
    en
    ISSN
    0960-7722
    ae974a485f413a2113503eed53cd6c53
    10.1111/j.1365-2184.2004.00320.x
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo.
    • Authors: Potten CS, Booth D, Haley JD
    • Issue date: 1997
    • Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    • Authors: Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB
    • Issue date: 2005 Sep
    • Transforming growth factor-B3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling.
    • Authors: Booth D, Haley JD, Bruskin AM, Potten CS
    • Issue date: 2000 Apr 1
    • A DPP-IV-resistant glucagon-like peptide-2 dimer with enhanced activity against radiation-induced intestinal injury.
    • Authors: Gu J, Liu S, Mu N, Huang T, Zhang W, Zhao H, Shu Z, Zhang C, Hao Q, Li W, Xue X, Zhang W, Zhang Y
    • Issue date: 2017 Aug 28
    • Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
    • Authors: Thymann T, Stoll B, Mecklenburg L, Burrin DG, Vegge A, Qvist N, Eriksen T, Jeppesen PB, Sangild PT
    • Issue date: 2014 Jun
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.